HPV Tumor DNA May Offer Early Warning of Cervical Cancer at High Risk of Relapse
(MedPage Today) -- HPV-positive circulating tumor (ct)DNA after chemoradiation (CRT) for cervical cancer had an independent association with worse outcomes, suggesting potential as a biomarker to guide decision-making, a prospective, multicenter... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 22, 2023 Category: Hematology Source Type: news
Nudging Parents Plus Auditing Providers Increased HPV Vaccine Uptake in Tweens
(MedPage Today) -- Reminding parents of tweens who were due for a human papillomavirus (HPV) vaccine increased uptake, especially when combined with auditing healthcare professionals after appointments, a cluster randomized trial showed.
Among... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 20, 2023 Category: Hematology Source Type: news
Reprogramming Tumors; Bad Stool Samples; Human Experiences in Cancer Care
(MedPage Today) -- A novel treatment that reprograms tumors to make them more responsive to immunotherapy showed promising activity in a preliminary clinical study of triple-negative breast cancer. (Roswell Park Comprehensive Cancer Center, Journal... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 18, 2023 Category: Hematology Source Type: news
ASTRO Updates Guidelines on Partial Breast Irradiation for Early Invasive Cancer
(MedPage Today) -- The American Society for Radiation Oncology (ASTRO) updated their guidelines on partial breast irradiation (PBI) for patients with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS).
These new guidelines take... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 16, 2023 Category: Hematology Source Type: news
'We're Not There Yet': CAR T-Cell Therapy for Renal Cell Carcinoma
(MedPage Today) -- NASHVILLE, Tenn. -- Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 16, 2023 Category: Hematology Source Type: news
Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma
(MedPage Today) -- NASHVILLE, Tenn. -- Building on the existing immune checkpoint inhibitor (ICI) platform, new treatment strategies for renal cell carcinoma (RCC) seek to adapt the cancer's immunity cycle to inform development of more effective... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 15, 2023 Category: Hematology Source Type: news
No Boost in Outcomes for Clear Cell RCC With Higher Belzutifan Dose
(MedPage Today) -- NASHVILLE, Tenn. -- A higher dose of belzutifan (Welireg) being investigated for advanced clear cell renal cell carcinoma (ccRCC) did not improve outcomes as compared with the usual dose in other settings, a randomized trial... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 13, 2023 Category: Hematology Source Type: news
Pancreatic Cancer Doesn't Have to Be a Death Sentence
(MedPage Today) -- According to the statistics, Scott Nelson and Steve Nelson shouldn't be alive today.
The Nelsons are brothers who live in Minnesota. They are two of the rare survivors of pancreatic cancer.
Scott's diagnosis came nearly 2 decades... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 13, 2023 Category: Hematology Source Type: news
Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma
(MedPage Today) -- NASHVILLE, Tenn. -- An investigational multitargeted drug produced objective responses in clear-cell renal cell carcinoma (ccRCC), irrespective of prior exposure to cabozantinib (Cabometyx), a small clinical trial showed.... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 12, 2023 Category: Hematology Source Type: news
Zoonotic Spillovers; DNA and RNA Testing for Cancer Risk
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 11, 2023 Category: Hematology Source Type: news
Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Mesh
(MedPage Today) -- Vitamin D supplementation may help lower the risk of chemotherapy-induced peripheral neuropathy in patients treated with paclitaxel. (Journal of the National Comprehensive Cancer Network)
At the same prostate-specific antigen... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 10, 2023 Category: Hematology Source Type: news
Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer
(MedPage Today) -- SEOUL, South Korea -- Treatment with the bispecific antibody ubamatamab alone or in combination with the PD-1 inhibitor cemiplimab (Libtayo) appeared to be safe and demonstrated activity in patients with recurrent ovarian cancer... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 10, 2023 Category: Hematology Source Type: news
Senate Confirms Monica Bertagnolli as Next NIH Director
(MedPage Today) -- The Senate voted 62-36 Tuesday to confirm surgical oncologist Monica Bertagnolli, MD, as the next director of the National Institutes of Health (NIH).
In May, President Biden tapped Bertagnolli, currently the director of the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 7, 2023 Category: Hematology Source Type: news
FDA Panel Backs High-Risk Designation for Salvaged Blood Irradiators
(MedPage Today) -- There are not enough safety and efficacy data for the FDA to issue a low-risk Class II device classification for salvaged blood irradiators used to prevent metastasis during surgery, an advisory panel agreed on Tuesday.
Members... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 7, 2023 Category: Hematology Source Type: news
T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancers
(MedPage Today) -- SEOUL, South Korea -- Durable responses with trastuzumab deruxtecan (T-DXd; Enhertu) in heavily pretreated HER2-expressing gynecologic cancers appeared to translate into clinically meaningful survival outcomes, findings from... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 7, 2023 Category: Hematology Source Type: news
